
Dr. Andreas Kany
Über
Andreas Kany promovierte bei HIPS-DDOP über die Entwicklung von Inhibitoren bakterieller Collagenasen. Aktuell ist er als Postdoc verantwortlich für in vitro ADME, Bioassay- und Formulierungsentwicklung
2025
Unlocking the Antiviral Arsenal: Structure-Guided Optimization of Small-Molecule Inhibitors against RSV and hCoV-229E
Karhan C, Sake S, Gunesch A, Grethe C, Hellwinkel B, Köhler N, Kiefer A, Hapko U, Kany A, Pietschmann T, Hirsch A (2025)
European journal of medicinal chemistryDOI: 10.1016/j.ejmech.2025.117282
2024
Isocyanides inhibit bacterial pathogens by covalent targeting of essential metabolic enzymes
Geißler A, Junca H, Kany A, Daumann L, Hirsch A, Pieper D, Sieber S (2024)
Chem. Sci. 15 (30): 11946-11955DOI: 10.1039/D4SC01940G
Clean Synthetic Strategies to Biologically Active Molecules from Lignin: A Green Path to Drug Discovery**
Afanasenko A, Wu X, Santi A, Elgaher W, Kany A, Shafiei R, Schulze M, Schulz T, Haupenthal J, Hirsch A, Barta K (2024)
Angewandte Chemie (Weinheim an der Bergstrasse, Germany) 136 (4)DOI: 10.1002/ange.202308131
Development of Fragment-Based Inhibitors of the Bacterial Deacetylase LpxC with Low Nanomolar Activity
Mielniczuk S, Hoff K, Baselious F, Li Y, Haupenthal J, Kany A, Riedner M, Rohde H, Rox K, Hirsch A, …, Sippl W, Holl R (2024)
Journal of medicinal chemistry 67 (19): 17363-17391DOI: 10.1021/acs.jmedchem.4c01262
Dipeptidic Phosphonates: Potent Inhibitors of Pseudomonas aeruginosa Elastase B Showing Efficacy in a Murine Keratitis Model
Kiefer A, Schütz C, Englisch C, Kolling D, Speicher S, Kany A, Shafiei R, Wadood N, Aljohmani A, Wirschem N, …, Haupenthal J, Hirsch A (2024)
In Vivo Activity Profiling of Biosynthetic Darobactin D22 against Critical Gram-Negative Pathogens
Kany A, Fries F, Seyfert C, Porten C, Deckarm S, Chacón Ortiz M, Dubarry N, Vaddi S, Große M, Bernecker S, …, Herrmann J, Müller R (2024)
ACS Infect. Dis. 10 (12): 4337-4346DOI: 10.1021/acsinfecdis.4c00687
Targeting Plasmodium falciparum IspD in the Methyl-d-erythritol Phosphate Pathway: Urea-Based Compounds with Nanomolar Potency on Target and Low-Micromolar Whole-Cell Activity
Willocx D, Bizzarri L, Alhayek A, Kannan D, Bravo P, Illarionov B, Rox K, Lohse J, Fischer M, Kany A, …, Diamanti E, Hirsch A (2024)
Journal of medicinal chemistry 67 (19): 17070-17086DOI: 10.1021/acs.jmedchem.4c00212
Thermo-amplifier circuit in probiotic E. coli for stringently temperature-controlled release of a novel antibiotic
Dey S, Seyfert C, Fink-Straube C, Kany A, Müller R, Sankaran S (2024)
Journal of biological engineering 18 (1)DOI: 10.1186/s13036-024-00463-y
Structure Revision of Halisphingosine A via Total Synthesis and Bioactivity Studies
Sauer M, Kany A, Götze S, Müller R, Beemelmanns C (2024)
Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202416036
Target-Directed Dynamic Combinatorial Chemistry Affords Binders of Mycobacterium tuberculosis IspE
Braun-Cornejo M, Ornago C, Sonawane V, Haupenthal J, Kany A, Diamanti E, Jézéquel G, Reiling N, Blankenfeldt W, Maas P, Hirsch A (2024)
ACS omegaDOI: 10.1021/acsomega.4c05537
Functionalization of Chlorotonils: Dehalogenil as Promising Lead Compound for In Vivo Application
Hofer W, Deschner F, Jézéquel G, Pessanha de Carvalho L, Abdel-Wadood N, Pätzold L, Bernecker S, Morgenstern B, Kany A, Große M, …, Herrmann J, Müller R (2024)
Angewandte Chemie (International ed. in English) 63 (19)DOI: 10.1002/anie.202319765
Discovery and optimization of thiazole-based quorum sensing inhibitors as potent blockers of Pseudomonas aeruginosa pathogenicity
Abdelsamie A, Hamed M, Schütz C, Röhrig T, Kany A, Schmelz S, Blankenfeldt W, Hirsch A, Hartmann R, Empting M (2024)
Eur. J. Med. Chem. 276DOI: 10.1016/j.ejmech.2024.116685
Target repurposing unravels avermectins and derivatives as novel antibiotics inhibiting energy-coupling factor transporters (ECFTs)
Haupenthal J, Rafehi M, Kany A, Lespine A, Stefan K, Hirsch* A, Stefan* S (2024)
Arch. Pharm.DOI: 10.1002/ardp.202400267
Novel 6-hydroxybenzothiazol-2-carboxamides as potent and selective monoamine oxidase B inhibitors endowed with neuroprotective activity
Al-Saad O, Gabr M, Darwish S, Rullo M, Pisani L, Miniero D, Liuzzi G, Kany A, Hirsch A, Abadi A, …, Catto M, Abdel-Halim M (2024)
European journal of medicinal chemistryDOI: 10.1016/j.ejmech.2024.116266
2023
Inhibitors of the Elastase LasB for the Treatment of Pseudomonas aeruginosa Lung Infections
Konstantinovic J, Kany A, Alhayek A, Abdelsamie A, Sikandar A, Voos K, Yao Y, Andreas A, Shafiei R, Loretz B, …, Haupenthal J, Hirsch A (2023)
ACS Cent. Sci. 9 (12): 2205-2215DOI: 10.1021/acscentsci.3c01102
New Genetically Engineered Derivatives of Antibacterial Darobactins Underpin Their Potential for Antibiotic Development
Seyfert C, Müller A, Walsh D, Birkelbach J, Kany A, Porten C, Yuan B, Krug D, Herrmann J, Marlovits T, Hirsch A, Müller R (2023)
J. Med. Chem.DOI: 10.1021/acs.jmedchem.3c01660
Clean Synthetic Strategies to Biologically Active Molecules from Lignin: A Green Path to Drug Discovery
Afanasenko A, Wu X, Santi A, Elgaher W, Kany A, Shafiei R, Schulze M, Schulz T, Haupenthal J, Hirsch A, Barta K (2023)
Angew. Chem. Int. Ed.DOI: 10.1002/anie.202308131
Disrupting Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Latent Replication with a Small Molecule Inhibitor
Berwanger A, Stein S, Kany A, Gartner M, Loretz B, Lehr C, Hirsch A, Schulz T, Empting M (2023)
Journal of medicinal chemistry 66 (15): 10782-10790DOI: 10.1021/acs.jmedchem.3c00990
New Genetically Engineered Derivatives of Antibacterial Darobac-tins Underpin their Potential for Antibiotic Development
Seyfert C, Müller A, Walsh D, Birkelbach J, Kany A, Porten C, Yuan B, Krug D, Herrmann J, Marlovits T, Hirsch A, Müller R (2023)
BookDOI: 10.26434/chemrxiv-2023-24tmj
Impact of Drug Administration Routes on the In Vivo Efficacy of the Natural Product Sorangicin a Using a Staphylococcus aureus Infection Model in Zebrafish Embryos
Fries F, Kany A, Rasheed S, Hirsch A, Müller R, Herrmann J (2023)
International journal of molecular sciences 24 (16)DOI: 10.3390/ijms241612791
Selective Activation of TRPC6 Ion Channel by Metallated Type-B Polyprenylated Polycyclic Acylphloroglucinols
Peslalz P, Kraus F, Izzo F, Bleisch A, El Hamdaoui Y, Schulz I, Kany A, Hirsch A, Friedland K, Plietker B (2023)
ManuscriptDOI: 10.26434/chemrxiv-2023-6w94r
The natural product chlorotonil A preserves colonization resistance and prevents relapsing Clostridioides difficile infection
Bublitz A, Brauer M, Wagner S, Hofer W, Müsken M, Deschner F, Lesker T, Neumann-Schaal M, Paul L, Nübel U, …, Fuchs T, Strowig T (2023)
Cell Host MicrobeDOI: 10.1016/j.chom.2023.04.003
Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof-of-Principle
Hamed M, Abdelsamie A, Rox K, Schütz C, Kany A, Röhrig T, Schmelz S, Blankenfeldt W, Arce-Rodriguez A, Borrero-de Acuña J, …, Hartmann R, Empting M (2023)
Adv. Sci. (Online)DOI: 10.1002/advs.202204443
2022
Screening of Natural Products and Small Molecules Uncovers Novel Coronavirus 1a/1b Frameshifting Inhibitors with Antiviral Properties
Kibe A, Elgaher W, Rand U, Zimmer M, Kany A, Hermann J, Müller R, Cicin-Sain L, Hirsch A, Caliskan N (2022)
SSRN JournalDOI: 10.2139/ssrn.4157446
N-Aryl Mercaptopropionamides as Broad-Spectrum Inhibitors of Metallo-β-Lactamases
Kaya C, Konstantinovic J, Kany A, Andreas A, Kramer J, Brunst S, Weizel L, Rotter M, Frank D, Yahiaoui S, …, Wichelhaus T, Hirsch A (2022)
Journal of medicinal chemistry 65 (5): 3913-3922DOI: 10.1021/acs.jmedchem.1c01755
Inhibitors of Pseudomonas aeruginosa virulence factor LasB
Ducho C, Hartmann R, Haupenthal J, Hirsch A, Kany A, Kaya C, Konstantinovic J, Voos K, Walter I, Yahiaoui S, …, Jumde R, Kiefer A (2022)
Patent A61K31/095; A61K31/10; A61K31/167; A61K31/4184; A61K31/426; A61K31/428; A61K31/4406; A61P31/04; C07C323/60; C07D213/74; C07D235/30; C07D277/46; C07D277/82; C07D333/36; C07F9/38; C07F9/40; (WO2022043322A1)
2021
N-Phenyl-3-Mercaptopropanamide Derivatives as Metallo-Beta-Lactamase Inhibitors for the Treatment of Bacterial Infections
Hartmann R, Konstantinovic J, Haupenthal J, Hirsch A, Kany A, Kaya C, Yahiaoui S, Wichelhaus T, Proschak E (2021)
Patent A61K31/5375; A61P31/04; C07C233/15; C07C233/25; C07C233/33; C07C233/43; C07C233/54; C07C319/02; C07C323/52; C07D295/22; (WO2021191219A1)
New PqsR Inverse Agonist
Schütz C, Empting M, Ahmed S, Hamed M, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61K31/506; A61P31/04; C07D401/12; C07D403/12; (WO2021136803A1)
Novel PqsR Inverse Agonists
Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2021)
Patent A61K31/4439; A61P31/04; C07D401/14; C07D417/14; (WO2021136805A1)
Substrate-Inspired Fragment Merging and Growing Affords Efficacious LasB Inhibitors
Kaya C, Walter I, Yahiaoui S, Sikandar A, Alhayek A, Konstantinovic J, Kany A, Haupenthal J, Köhnke J, Hartmann R, Hirsch A (2021)
Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202112295
A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms
Schütz C, Ho D, Hamed M, Abdelsamie A, Röhrig T, Herr C, Kany A, Rox K, Schmelz S, Siebenbürger L, …, Lehr C, Empting M (2021)
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 8 (12)DOI: 10.1002/advs.202004369
2020
Flexible Fragment Growing Boosts Potency of Quorum-Sensing Inhibitors against Pseudomonas aeruginosa Virulence
Zender M, Witzgall F, Kiefer A, Kirsch B, Maurer C, Kany A, Xu N, Schmelz S, Börger C, Blankenfeldt W, Empting M (2020)
ChemMedChem 15 (2): 188-194DOI: 10.1002/cmdc.201900621
Micro-rheological properties of lung homogenates correlate with infection severity in a mouse model of Pseudomonas aeruginosa lung infection
Murgia X, Kany A, Herr C, Ho D, Rossi C, Bals R, Lehr C, Hirsch A, Hartmann R, Empting M, Röhrig T (2020)
Scientific Reports 10 (1)DOI: 10.1038/s41598-020-73459-5
N -Aryl-3-mercaptosuccinimides as Antivirulence Agents Targeting Pseudomonas aeruginosa Elastase and Clostridium Collagenases
Konstantinovic J, Yahiaoui S, Alhayek A, Haupenthal J, Schönauer E, Andreas A, Kany A, Müller R, Koehnke J, Berger F, …, Brandstetter H, Hirsch A (2020)
J. Med. Chem. 63 (15): 8359-8368DOI: 10.1021/acs.jmedchem.0c00584
Novel PqsR Inverse Agonists
Hamed M, Ahmed S, Empting. M., Schütz C, Hartmann R, Röhrig T, Kany A, Hirsch A (2020)
Patent (EP20150119)
2018
Tackling Pseudomonas aeruginosa Virulence by a Hydroxamic Acid-Based LasB Inhibitor
Kany A, Sikandar A, Yahiaoui S, Haupenthal J, Walter I, Empting M, Köhnke J, Hartmann R (2018)
ACS chemical biology 13 (9): 2449-2455DOI: 10.1021/acschembio.8b00257